Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated. The full version of the new guidelines is available on the AASLD Web site at http://www.aasld.org/practiceguidelines/ Documents/Bookmarked%20Practice%20Guidelines/ HCCUpdate2010.pdf. Here, we briefly describe only new or changed recommendations.

/pdf/aasld-practice-guideline-management-of-hepatocellular-51bocalv0r.pdf

AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update

https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.20933

Management of hepatocellular carcinoma.

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1053/jhep.2003.50193

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.20948

Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.

A model to predict survival in patients with end-stage liver disease

A revised natural history model for primary sclerosing cholangitis obviates the need for liver histology

Background: Interferon-α is effective in only a small number of patients with chronic hepatitis C, although prolonged treatment may increase the response rate. There is concern that the expense of ...

Cost-Effectiveness of 6 and 12 Months of Interferon-α Therapy for Chronic Hepatitis C

Patients with nonalcoholic steatohepatitis (NASH) may develop progressive liver dysfunction necessitating liver transplantation (OLT) We report the incidence of recurrent disease and outcome in patients undergoing OLT for NASH Patients transplanted for NASH were identified according to pretransplant and explant liver histology Patients with significant alcohol consumption were excluded Medical records were reviewed to extract pre- and posttransplant data, including sequential body weight, biochemistry, and graft histology Of 622 liver explants, eight patients had features consistent with NASH All patients were female with a median age of 58 Seven patients were diagnosed with NASH preoperatively, including three who had undergone jejunoileal bypass One patient was diagnosed as cryptogenic cirrhosis At a median of 15 months following OLT, all of the eight patients were alive with no graft failure Six patients developed persistent fatty infiltration in their graft, three of whom had accompanying hepatocellular degeneration, consistent with a diagnosis of recurrent NASH In two patients, transition from mild steatosis to steatohepatitis and early fibrosis was observed over one to two years The patients who did not develop recurrent steatosis had significant weight loss following transplantation, although the length of follow-up was relatively short Patients undergoing OLT for NASH may develop recurrent steatosis shortly after transplantation, with possible progression to steatohepatitis and fibrosis Although longer follow-up is necessary to determine the eventual prognosis related to the recurrent fat and fibrosis in the graft, patients with endstage liver disease due to NASH should be considered good candidates for OLT

Recurrence of nonalcoholic steatohepatitis following liver transplantation.

https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.510290607

The relative role of the child‐pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis

W. R. Kim

Papers

A model to predict survival in patients with end-stage liver disease

A revised natural history model for primary sclerosing cholangitis obviates the need for liver histology

Cost-Effectiveness of 6 and 12 Months of Interferon-α Therapy for Chronic Hepatitis C

Recurrence of nonalcoholic steatohepatitis following liver transplantation.

The relative role of the child‐pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis